venerdì, 26 novembre 2021
9 Settembre 2019

Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 2-5 September 2019

Sep 6, 2019 – EMA’s safety committee (PRAC) has started a review of data on skin cancer in patients using Ingenol mebutate (LEO), a gel for treating actinic keratosis, a skin condition caused by too much sunlight exposure. The review was triggered by data from several studies showing a higher number of skin cancer cases including cases of squamous cell carcinoma in patients using Ingenol mebutate. In order to conclude on whether Ingenol mebutate increases the … (leggi tutto)